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X-linked dominant incontinentia pigmenti (IP) and X-linked recessive anhidrotic ectodermal
dysplasia with immunodeficiency (EDA-ID) are caused by loss-of-function and hypomorphic
IKBKG (also known as NEMO) mutations, respectively. We describe a European mother
with mild IP and a Japanese mother without IP, whose 3 boys with EDA-ID died from ID. We
identify the same private variant in an intron of IKBKG, IVS4+866 C>T, which was inherited
from and occurred de novo in the European mother and Japanese mother, respectively.
This mutation creates a new splicing donor site, giving rise to a 44-nucleotide pseudoexon
(PE) generating a frameshift. Its leakiness accounts for NF-kB activation being impaired but
not abolished in the boys’ cells. However, aberrant splicing rates differ between cell types,
with WT NEMO mRNA and protein levels ranging from barely detectable in leukocytes to
residual amounts in induced pluripotent stem cell–derived (iPSC-derived) macrophages,
and higher levels in fibroblasts and iPSC-derived neuronal precursor cells. Finally, SRSF6
binds to the PE, facilitating its inclusion. Moreover, SRSF6 knockdown or CLK inhibition
restores WT NEMO expression and function in mutant cells. A recurrent deep intronic
splicing mutation in IKBKG underlies a purely quantitative NEMO defect in males that is
most severe in leukocytes and can be rescued by the inhibition of SRSF6 or CLK.
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Introduction
The IKBKG gene, also known as NEMO, encodes the NF-κB essen-
tial modulator (NEMO) (1, 2). NEMO encodes the third regulatory 
subunit of the IκB kinase (IKK) complex and is also called IKKγ 
(3–5). NEMO was discovered in 1998 as a component required 
for the activation of NF-κB via the canonical pathway (1–4, 6). In 
2000, loss-of-function mutations of IKBKG were shown to abol-
ish canonical NF-κB activation and to underlie X-linked dominant 
(XD) incontinentia pigmenti (IP) (phenotype MIM #308300), a 
multisystem disorder affecting the skin and its appendages in all 
affected women, and the CNS in most but not all women (7, 8). 
XD-IP has an estimated prevalence of 1 to 10 cases per million 
births. A defining feature of the IP phenotype and the IP-causing 
genotype is that they are both lethal in utero in males. The absence 
of a functional NEMO protein renders cells apoptotic, resulting 
in skewed X inactivation in most if not all of the cells of affected 
females and early fetal death in affected males. In 2001, hypomor-
phic IKBKG mutations were found to impair NF-κB activation and 
to cause X-linked recessive (XR) anhidrotic ectodermal dysplasia 
with immunodeficiency (EDA-ID) (phenotype MIM #300291) (9, 
10). Affected men display typical signs of EDA, including sparse 
hair, eyebrows, and eyelashes, hypohidrosis, hypodontia, and con-
ical incisors, together with an ID not seen in patients with muta-
tions of ectodysplasin A or its receptor chains (11). Female carriers 
in kindreds with EDA-ID are asymptomatic or show mild signs 
of IP, mostly restricted to the persistence of cutaneous Blaschko 
lines and sparse or conical incisors (9, 10, 12–14). Indeed, although 
EDA-ID and IP are clearly different disorders in men, they have a 
phenotypic overlap in women, in whom very mild forms of IP may 
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exons and their flanking intron splice sites, including the promot-
er and introns, have been reported in families with IP or EDA-ID. 
Another form of EDA-ID is autosomal dominant (AD) and caused 
by gain-of-function mutations of the NFKBIA gene (29, 30). Howev-
er, approximately 10% of sporadic and familial cases of both IP and 
EDA-ID remain genetically unexplained.
The human IKBKG gene is located on chromosome Xq28, close 
to the IKBKGP pseudogene, which is located 71 kb away, closer to 
the telomeric region on the opposite strand. IKBKGP has 8 exons 
identical to the corresponding IKBKG exons, but it lacks exons 1 (a, 
b, c, d) and 2 (which contains the IKBKG initiation codon) (Figure 
1A). IKBKGP is not transcribed, as it lacks promoter and transcrip-
tion initiation sites. The 8 introns separating the IKBKGP exons also 
have nucleotide sequences very similar to those of IKBKG (8,879 of 
8,884 nucleotides are identical). The detection of IKBKG mutants 
has therefore always been hindered by the presence of IKBKGP (7, 
31–33). Sanger sequencing of the mRNA products of IKBKG typi-
cally overcomes this problem, as the related pseudogene is not 
transcribed. However, this approach is most suitable for the detec-
tion of mutations within exons and their flanking regions, which 
are likely to alter the mRNA structure. Consequently, noncoding 
IKBKG mutations have not been reported, neither in families with 
IP nor in families with EDA-ID. Deep intronic causal mutations 
of other disease-causing genes were detected by a gene-specific 
approach in patients without mutations of the exons of a specific 
gene (e.g., β-thalassemia [refs. 34, 35], Duchenne muscular dys-
trophy [ref. 36], Usher syndrome [ref. 37], chronic granulomatous 
disease [ref. 38]). Moreover, the genetic etiology of X-linked reces-
sive reticulate pigmentary disorder (XR-PDR), a syndromic pri-
mary ID, was recently determined through the identification of a 
recurrent deep single-nucleotide mutation within 1 of the introns of 
be caused by severely hypomorphic IKBKG mutations (8). XD-IP 
and XR-EDA-ID are allelic, as they are caused by different muta-
tions of the same gene.
Approximately 78% of known cases of XD-IP are due to a recur-
rent deletion (NEMOΔ4–10), removing exons 4–10 and causing losses 
of both the production and function of NEMO (7, 15, 16). In two-
thirds of these patients, the deletion occurs de novo in the mother’s 
germline (17). Other typical XD-IP–causing lesions include frame-
shift indels (n = 32), nonsense mutations (n = 16), and essential splice 
site mutations that are not leaky and cause frameshift or in-frame 
deletions of 1 or more exons (n = 6), whereas missense mutations 
(n = 7) and in-frame indels (n = 1) (8, 18) are much rarer. By contrast 
and consistent with their hypomorphic nature, most mutations 
underlying XR-EDA-ID are missense mutations or in-frame indels. 
In total, 57 IKBKG mutations have been reported to date: 27 are mis-
sense, 5 are in-frame indels, and 1 is a stop-loss mutation, whereas 
only 7 nonsense mutations and 9 frameshift indels have been iden-
tified. Fifteen of the 16 nonsense mutations and frameshift indels 
affect the last 3 exons (3 in exon 8, 2 in exon 9, 10 in exon 10) encod-
ing the ZF domain of NEMO, the truncation of which does not 
abolish NEMO activity (8–10, 19–21). The remaining mutation is a 
premature stop codon at position 38, which is hypomorphic because 
of the reinitiation of translation (13, 22). The other EDA-ID–causing 
lesions include splicing mutations that are in-frame and/or leaky 
(n = 7) and an exon duplication (n = 1), resulting in the expression 
of residual levels of dysfunctional mutant NEMO proteins, with or 
without residual expression of the full-length protein (23–26). Final-
ly, 2 mutations of the exon 1b splice site (c.-16+1 G>T, c.-16 G>C) 
encoding the 5′-UTR affects only 1 of the 4 alternative transcripts. 
The mechanism underlying the hypomorphism of this mutation 
is unclear (27, 28). Intriguingly, no mutations outside the IKBKG 
Figure 1. Pedigrees. (A) Schematic representation of IKBKG and the surrounding region between positions X: 153,700,000 and X: 154,000,000. IKBKG and 
IKBKGP are indicated in red, the 35-kb duplication in green, and the region masked for the reanalysis in black. The variants reported in the 1kG and dbSNP 
134 databases are shown in blue/red and gray, respectively. (B) Pedigrees of kindreds A and B. Patients with EDA-ID are indicated in black, and the mother 
with mild IP is indicated in gray. 
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ing IKBKGP (chrX: 153,860,736-153,876,549) artificially, replac-
ing these nucleotides by a stretch of N nucleotides in the reference 
genome. This results in the raw reads obtained with the modified 
hg19-b37 reference human genome mapping only to the IKBKG 
locus, making it easier for Genome Analysis Toolkit (GATK) soft-
ware to call the variants (Figure 2A; see Methods). The application 
of this strategy to align whole-genome sequencing (WGS) raw data 
for IKBKG for P2 and his mother revealed the presence of only 1 
private variant at position X: 153,787,731 (IVS4+866 C>T) (Supple-
mental Figure 4, A and B). We then amplified the IKBKG and IKB-
KGP loci with specific PCR primers (Figure 2B), which confirmed 
the hemizygous nature of IVS4+866 C>T in P2, its heterozygous 
nature in his mother, and its absence from P2’s healthy brother 
(Figure 2C). In parallel, specific amplification of the IKBKGP locus 
and sequencing of the position equivalent to IVS4+866 C>T (X: 
153,873,196 for IKBKGP) showed the sequence present to be WT 
in P2, his mother, and all 3 healthy controls tested. No variants at 
the IVS4+866 C>T position in IKBKG or the equivalent position 
in IKBKGP were identified in public databases (1000 Genomes 
[1kG], n = 2,504 individuals, gnomAD, n = 15,496 individuals, 
Bravo, n = 62,784 individuals). We thus selected the deep intron-
ic variant IVS4+866 C>T as a candidate mutation at the IKBKG 
locus in this family. We performed Sanger sequencing on intron 
4 in 4 sporadic, genetically undiagnosed, unrelated cases involv-
ing 3 women with IP and a boy with severe ID and subtle signs of 
EDA. We found the exact same mutation in the boy (P3). P3 was 
from Japan and died of recurrent bacterial infections at the age 
of 6 months (Figure 1B; see clinical report in the Supplemental 
Data). His mother is healthy and displays no signs of IP. Familial 
segregation patterns confirmed the presence of the IVS4+866 
C>T mutation at the IKBKG locus and its de novo occurrence (Fig-
ure 2C). These findings therefore indicate that the IVS4+866 C>T 
mutation of IKBKG is recurrent as a result of a hotspot rather than 
a founder effect, providing further support for the hypothesis that 
it is disease causing.
Identification of rare and common variants at the IKBKG locus 
by WGS with 1kG Project data. Intriguingly, the specific amplifica-
tion of IKBKG also revealed the presence of another variant at X: 
153,787,729, IVS4+864 A>G, in 2 of the 3 unrelated control genom-
ic DNA (gDNA) samples tested. The lack of reported variants at 
positions X: 153,787,729 (IVS4+864 A>G) and X: 153,787,731 
(IVS4+866 C>T) in the gnomAD and Bravo databases does not 
necessarily imply that the apparently private mutation IVS4+866 
C>T is not really a rare variant or even a polymorphism. Indeed, 
only 65 variants were reported in gnomAD for the 12.6-kb dupli-
cated region of the genome encompassing IKBKG (from intron 2 
to the 3′-UTR), whereas it is generally estimated that the mean 
frequency of single nucleotide variants is 60/kb in the human 
genome, based on 1kG Project data (Figure 1A) (44). We there-
fore assessed allelic diversity at the IKBKG locus. We applied the 
strategy described above to the 1kG Project data for 2504 healthy 
individuals, to reanalyze the IKBKG locus (Figure 2A). Using the 
sex of the individuals, as recorded in the database, we estimated 
the minor allele frequency (MAF) of all variants. We first validat-
ed our set of variants by comparing our calculated MAF with that 
obtained from the 1kG data. Excluding the duplicated region con-
taining IKBKG and IKBKGP from this analysis, we found a very 
the POLA1 gene (39, 40). Disease-causing deep intronic mutations 
typically create a pseudoexon (PE), which is rarely canonical, often 
resulting in suboptimal splicing (37). Targeted genetic studies have 
recently suggested that deep intronic disease-causing mutations 
may be more common than previously thought, because at least 
77 genes have been found to contain disease-causing mutations 
of this type (41, 42). We studied 2 families, a European family in 
which the mother had very mild IP and lost 2 sons to EDA-ID at the 
ages of 1 and 9 months, and a Japanese family in which the mother 
was healthy but lost a son to EDA-ID at the age of 6 months. In all 
3 boys, the ID was much more severe than the manifestations of 
EDA. No mutations were detected in the exons or flanking intronic 
regions of IKBKG.
Results
A family with EDA-ID and IP without mutations in the exons of 
IKBKG. We first investigated 2 brothers born to a European mother 
with very mild IP (case report, Figure 1B, kindred A) at 36 and 37 
weeks of gestation. P1 died at the age of 21 days from sepsis and 
meningitis due to Klebsiella, with no antecedents, and his young-
er brother P2 died at the age of 9 months from respiratory syncy-
tial virus pneumonitis after a history of recurrent viral, bacterial, 
and fungal infections in the absence of fever or biological signs of 
inflammation (case report, Supplemental Table 1; supplemental 
material available online with this article; https://doi.org/10.1172/
JCI124011DS1). P2 had mild signs of EDA, including dry skin 
and sparse hair, whereas P1 was too young to be evaluated for 
such features. A younger brother (A.II.3), now aged 15 years, has 
remained healthy, as has his newborn sister, who is now 6 months 
of age (A.II.4). Given the mild IP in the mother, signs of EDA in at 
least 1 boy, and the early death from infection of 2 boys, an IKBKG 
mutation was suspected. Skewed X-inactivation was observed in 
the mother’s NK cells, monocytes, granulocytes, and, to a lesser 
extent, dermal fibroblasts (Supplemental Figure 1). An analysis 
of X-chromosome microsatellites and copy number variations 
(CNVs) in the mother, P1, P2, and their healthy brother (A.II.3) 
confirmed that a haplotype on Xq28 encompassing IKBKG was 
common to the 2 infants who died, but not to their healthy broth-
er, and was inherited from their mother (Supplemental Figure 2). 
Sanger sequencing of the IKBKG exons at the genomic level (with-
out discrimination between the IKBKG and IKBKGP exons) (Figure 
1A) and of the amplified IKBKG cDNA (including all 4 transcripts 
encoding the only validated protein isoform) identified no rare or 
private variants in the patients. Major genomic rearrangements 
(translocations, large deletions or insertions) were also excluded 
by Southern blotting (Supplemental Figure 3), high-density arrays 
for CNV detection, and FISH (data not shown). Finally, whole- 
exome sequencing (WES) identified no candidate mutations in 
IKBKG or elsewhere on the X chromosome.
A recurrent deep mutation in an intron of IKBKG. We thus 
sequenced the whole genome of P2 and his mother. Next-gen-
eration sequencing (NGS) software cannot call variants on long 
stretches of repetitive DNA (43). The region of Xq28 contain-
ing the IKBKG locus is characterized by a 35-kb low-copy repeat 
(LCR) (Figure 1A). Variants at the IKBKG locus are thus partly 
uncalled. One solution for overcoming the problem posed by this 
35-kb duplication (7, 17) is to mask the duplicated region contain-
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IKBKG and IKBKGP (Supplemental Figure 5). Of the identified 
variants, 51 were located in introns, 67 were downstream of the 
last exon, or, more rarely, 6 were in the 3′-UTR, and 1 was within 
a splicing region. We found only 1 missense (E355K) mutation to 
be hemizygous, albeit with weak coverage (4 reads). However, we 
found this variant in the heterozygous state in 2 unrelated females, 
suggesting that it may be a true rare variant. The remaining 383 
variants had been called as heterozygous in females or males or 
both. In such cases, it was not possible to attribute the variant to 
either IKBKG or IKBKGP by this approach. Of these variants, 189 
were located in introns, 140 were downstream of the last exon, or, 
strong correlation (R2 = 0.94) for all reported variants and for the 
genes immediately upstream of IKBKG (FAM3; R2 = 0.94) and 
downstream of IKBKGP (GAB3; R2 = 0.93) (Figure 3A). Focusing 
on the IKBKG region (X: 153,784,100–153,799,445), we identified a 
total of 509 variants (Supplemental Table 2). Only 24 of these vari-
ants were reported in the 1kG, ESP6500, and gnomAD databases 
(Figure 3B). Forty-five variants reported in the 1kG, ESP6500, and 
gnomAD databases were not identified in our analysis. We clas-
sified the 509 variants into groups on the basis of zygosity calls. 
In total, 126 variants were hemizygous in males or homozygous in 
females, or both, implying that the variants were carried by both 
Figure 2. Genomic strategies to identify IKBKG variants. (A) Comparison of WGS mapping results between the classical and alternative (masking of the 
IKBKGP locus) strategies. The red/blue reads are the mapped sequences that can be used for variant calls (mappy quality score [MQ] >20), and the gray/
white reads are the mapped sequences for which no variant could be called (MQ = 0). The duplicated region is indicated with a green bar and the masked 
region with a black bar. (B) Specific amplification by PCR of the full-length (top) or partial (bottom) IKBKG locus. gDNA from 2 controls (CTL), a patient 
(P2) and his mother, and from 2 NEMOΔ4–10 (from 1 male and 1 female patient) SV40 immortalized fibroblast lines was used as the template. (C) IKBKG and 
IKBKGP DNA sequence electropherograms for controls, SV40-immortalized fibroblasts from a patient (P2) and his mother and a healthy brother (A.II.3), 
and for the leukocytes from a patient (P3) and his mother.
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in base pairing between the +861 to +867 stretch of IKBKG intron 
4 and the U1snRNA (Supplemental Figure 7), but with no pairing 
at positions –1, –2, or –3. Exon trapping showed that the IVS4+866 
C>T mutation led to the inclusion of a PE within intron 4 of IKB-
KG. Direct sequencing confirmed the presence of a 44-nt PE by 
identification of the cryptic acceptor site with a conserved branch 
point (YUNAY sequence) (46), polypyrimidine tract (PPT) (C/U 
= 81.8%), and junction site (AG/A) (Supplemental Figures 7 and 
8). Conversely, the A/G SNP at the IVS4+864 position had no 
effect on pairing with the pseudouridine of U1snRNA at the +4 
position (Supplemental Figure 7) and thus had no effect on the 
splicing of IKBKG intron 4 (Supplemental Figure 8). We then ana-
lyzed the consequences of IVS4+866 C>T in terms of the mRNA 
present in the patients’ cells. We first analyzed the amounts of 
IKBKG transcripts by Northern blotting. Immortalized mRNAs 
from SV40-transformed fibroblasts from a healthy control, P2, 
his mother, and a woman with IKBKGΔ4–10 were hybridized with 
full-length IKBKG cDNA. P2 had 75% less mRNA than did the 
controls, whereas his mother had only slightly less mRNA than 
did the controls (Figure 4B). This result was confirmed by reverse 
transcription quantitative PCR (RT-qPCR), which showed P2 to 
have approximately 75% as much IKBKG mRNA as the controls 
(Figure 4C). The whole-blood sample obtained from P3 contained 
approximately 30% less IKBKG mRNAs than did a sample from a 
more rarely, 20 were in the 3′-UTR, and 1 was within the splicing 
region. Surprisingly, however, 33 of these variants were located in 
coding exons, and this group included 3 nonsense or indel frame-
shift variants, 21 missense variants, and 9 synonymous variants 
(Supplemental Table 3). Given the clinical impact of deleterious 
mutations of IKBKG, the 3 most deleterious variants (nonsense 
and frameshift indels) identified were probably located in IKB-
KGP. We thus report what to our knowledge is the first compre-
hensive genetic analysis of the IKBKG locus, with a MAF for each 
variant and population (with a factor 2 approximation) (Supple-
mental Figure 5 and Supplemental Table 2). In this analysis, we 
did not find IVS4+866 C>T, whereas IVS4+864 A>G was clearly 
shown to be a polymorphism, with a MAF of 0.51 in the general 
population. This approach also confirmed that the 2 families with 
EDA-ID carried a private IKBKG variant, consistent with this vari-
ant being an IP-causing one in the European mother and EDA-ID 
causing in her sons and in P3.
The IVS4+866 C>T mutation creates a suboptimal donor site 
for PE inclusion. We analyzed the functional consequences of 
IVS4+866 C>T. In silico analyses with ESE Finder (45) and similar 
software predicted potential splice donor sites following introduc-
tion of the IVS4+866 C>T mutation (Figure 4A and Supplemen-
tal Figure 6, A–C). We detected an acceptor site upstream of the 
mutation (+817) that, in the presence of IVS4+866 C>T, resulted 
Figure 3. Reanalysis of the IKBKG locus with 1kG Project data. (A) Correlation between the MAF of each variant in this study and the MAF reported in the 
1kG Project. Plots show all the variants except for the IKBKG locus and the correlation for variants of FAM3 and GAB3, respectively. (B) Magnification of 
the IKBKG locus, for a comparison of the variants identified in this study (blue circles) with those reported in the various databases (red, orange, and green 
circles correspond to 1kG, ExAC, and ESP6500 databases, respectively). IKBKG exons are depicted by red bars and G6PD by gray bars.
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healthy control (Figure 4C). We then analyzed the entire coding 
sequence (CDS) of IKBKG using cDNA prepared from the fibro-
blasts of P2 and whole-blood cells from P3 and healthy controls. 
This analysis confirmed the lower levels of normal transcripts and 
the presence of aberrant transcripts in the patients’ cells (Figure 
4D). We identified and quantified IKBKG mRNA structures by TA 
cloning and Sanger sequencing of molecular clones of these ampl-
icons from the controls, P2, and P3. In control SV40-immortalized 
fibroblasts, 65% of the cDNAs obtained were full length and 32% 
had skipped exon 5 (Supplemental Table 4). In SV40-immortal-
ized fibroblasts from P2, we detected not only the WT transcript 
but also new aberrant transcripts, accounting for approximately 
one-third of the total mRNA from this gene. All these new aber-
rant transcripts contained the 44-nt PE (Figure 4A), either alone 
or with the 3′ or 5′ end of intron 4 (depicted as exons 4A and 5A 
in Figure 4A, Figure 4E, Supplemental Figure 7B, Supplemental 
Figure 9, and Supplemental Table 4). The same approach showed 
a whole-blood sample from P3 to contain only 1% full-length WT 
transcript, strongly contrasting with the 58% detected in a sample 
from a healthy donor (Figure 4E and Supplemental Table 4). RNA-
Figure 4. The IVS4+866 C>T intronic mutation causes aberrant IKBKG splicing. (A) Description of the impact of the mutation on the IKBKG transcript, 
focusing on the junction of exons 4 and 5. The PE (blue rectangle) was found in P2 and P3 but not in the controls. White rectangles indicate exons 4 
and 5, and black rectangles indicate the alternative donor site (exon 4A) or the alternative acceptor site (exon 5A) found in the patients and controls. 
The IVS4+866 C>T mutation is indicated by a red arrow. (B) Northern blot analysis of purified mRNA from a control, P2 and his mother, and NEMOΔ4–10/Y 
SV40-immortalized fibroblasts. The mRNAs were hybridized with a full-length 32P-labeled IKBKG or ACTB cDNA. (C) RT-qPCR analysis of total cDNA from 
controls, P2 and his mother, and NEMOΔ4–10/Y SV40-immortalized fibroblasts, and of whole-blood cells from a control and P3. Data are expressed as ΔΔCt 
normalized against GAPDH. The mean ± SD of the data obtained from 8 independent experiments is shown for the fibroblasts. The mean of triplicate 
experiments is shown for whole-blood cells and is representative of 2 independent experiments. (D) Full-length IKBKG amplification of purified mRNA 
from control and P2 SV40-immortalized fibroblasts as well as from whole-blood cells from a control and P3. (E) Schematic representation of IKBKG 
transcripts obtained after TA cloning experiments on controls, P2, and P3 from D. Approximately 100 clones were sequenced, and the results are expressed 
as percentages. (F) Sashimi plot of the RNA-Seq data from SV40-immortalized control (CTL1 and CTL2) and P2 fibroblasts. The red arrow indicates the 
position of IVS4+866 C>T and the new exon. Black and red numbers indicates the number of reads overlapping 2 consecutive exons. E1, E2, etc., exon 1, 
exon 2, etc.; M, molecular weight ladder; MW, molecular weight.
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Seq data analysis of the mRNAs extracted from the immortalized 
fibroblasts of P2 and 2 controls confirmed the lower levels of 
IKBKG mRNA (approximately 50% lower) in P2, together with the 
presence of these new transcripts (Figure 4F). The fibroblasts and 
whole-blood cells from P2 and P3 contained mutant IKBKG tran-
scripts (carrying a 44-nt PE) encoding proteins with a premature 
stop codon, with moderate and profound decreases, respectively, 
in WT full-length transcript levels
Cell type–dependent effect of IVS4+866 C>T on aberrant IKBKG 
splicing. We investigated in greater detail the cell type dependence 
of WT IKBKG expression in the context of the IVS4+866 C>T 
mutation. Our previous results were highly consistent with the cell 
type–dependent pattern of the X-skewing inactivation observed 
in the affected mother of P1 and P2, as some leukocyte subsets 
(monocytes, NK cells, and granulocytes) displayed greater skew-
ing than others (B and T cells) and than fibroblasts (Supplemen-
tal Figure 1). We hypothesized that the intensity of the alternative 
splicing generated by IVS4+866 C>T might be dependent on cell 
type. We tested this hypothesis by using induced pluripotent stem 
cell (iPSC) lines established from the leukocytes of P3. We mea-
sured the levels of WT and alternative IKBKG transcripts in undif-
ferentiated iPSCs, iPSC-derived myeloid cells (iPSC-MLs), and 
iPSC-derived neuronal precursor cells (iPSC-NPs) (Supplemental 
Figure 10). RT-qPCR on IKBKG revealed that transcript levels in 
P3 iPSC-MLs were one-half those in control cells (Figure 5A). The 
amplification of IKBKG cDNA demonstrated the presence of aber-
rant products in iPSC-MLs (Figure 5B). TA cloning revealed that 
the ratio of full-length WT to aberrant IKBKG transcripts differed 
markedly between undifferentiated iPSCs, iPSC-MLs, and iPSC-
NPs (Figure 5C). iPSCs from P3 produced approximately 17% WT 
transcripts, whereas P3-derived iPSC-NPs produced approximate-
ly 35% WT transcripts, a level similar to that obtained with dermal 
fibroblasts from P2 (Figure 4E). WT transcript levels were as low 
as 3% in P3-derived iPSC-MLs, a level similar to that reported for 
whole-blood cells from P3 (Figure 4E). Interestingly, transcripts 
containing the PE plus exon 5A were abundant in whole-blood 
cells from P3 and in iPSC-MLs (Figure 4A and Supplemental Table 
4), suggesting that the alternative acceptor site for exon 5A was 
better recognized in whole-blood cells and iPSC-MLs than in the 
other cell types tested. We also quantified the NEMO protein lev-
els in these cell lines, confirming lower (approximately 25% lower) 
but detectable levels of WT protein in SV40-immortalized fibro-
blasts from P2, whereas this protein was almost undetectable in 
PBMCs from P3 (Figure 5, D and E). Quantification of NEMO pro-
tein levels against β-actin showed them to be approximately 40% 
lower in iPSC-MLs from P3 than in undifferentiated iPSCs and 
approximately 6.6 times higher in iPSC-NPs (Figure 5F). NEMO 
protein levels therefore depended on cell type and were correlat-
Figure 5. The level of aberrant IKBKG splicing caused by IVS4+866 C>T mutation is cell type dependent. (A) RT-qPCR analysis of total cDNA from iPSCs, 
iPSC-MLs, and iPSC-NPs obtained from a control and P3. Data were obtained in triplicate and are expressed as ΔΔCt normalized against GAPDH. Represen-
tative results of 2 independent experiments are shown. (B) RT-qPCR amplification of full-length IKBKG from RNA extracted from control and P3-derived 
iPSCs, iPSC-MLs, and iPSC-NPs. (C) Percentage of IKBKG transcripts obtained after TA cloning experiments on P3-derived iPSCs, iPSC-MLs, and iPSC-NPs 
from B. (D–F) NEMO protein levels in total cell extracts from (D) SV40-immortalized fibroblasts established from controls, P2, a patient with a hypomorphic 
IKBKG mutation (NEMOX420W/Y), and a patient with complete NEMO deficiency (NEMOΔ4–10/Y), (E) frozen PBMCs from a control and P3, and (F) P3-derived 
iPSCs, iPSC-MLs, or iPSC-NPs with 3 independent clones. Numbers indicate the expression levels of NEMO relative to GAPDH (D and E) or β-actin (F).
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only the X420W-mutated NEMO protein (9). We observed a simi-
lar but more pronounced defect in P3-derived iPSC-Mϕ, which had 
very low levels of WT NEMO expression. Collectively, these find-
ings suggest that the presence of 25% less of the normal levels of 
WT NEMO severely impairs but does not abolish NF-κB activation 
in fibroblasts, leukocytes, and iPSC-Mϕ. The mutation found in the 
2 kindreds studied here is therefore severely hypomorphic but not 
loss of function, even in hematopoietic cells, in which the protein 
was barely, if at all, detectable, accounting for both the severe form 
of EDA-ID seen early in the lives of the 3 boys who died and the 
mild IP seen in the European mother.
CDC-like kinase inhibitor restores the normal splicing of IKBKG. 
We analyzed the mechanisms underlying the PE inclusion caused 
by the mutation IVS4+866 C>T. RNA-pulldown assays showed the 
PE donor to have a greater affinity for U1snRNP, with the detec-
tion of U1-70k, U1-A, U1-C, and SmB/B′ subunits following the 
introduction of IVS4+866 C>T (Figure 7, A and B). However, the 
absence of base pairing to U1snRNA at positions –1, –2, and –3 
renders this donor suboptimal (Supplemental Figure 7A) and sug-
gests that its recognition is assisted by a splicing enhancer. Serine/
arginine-rich splicing factor (SRSF) belongs to a major family of 
trans-acting splicing factors that act as exonic splicing enhancers 
(ESEs), facilitating spliceosomal complex formation at suboptimal 
cassette exons (47, 48). RNA-binding assays for the identification 
of the SRSF-binding site revealed a high affinity of SRSF6 for the 
PE sequence (Figure 7C), suggesting the presence of an SRSF6-de-
pendent cis regulatory element. We therefore hypothesized that 
the inhibition of SRSF6 activity might repress PE inclusion and 
restore the expression of functional IKBKG. We observed a partial 
restoration of NEMO expression in iPSC-Mϕ from P3 following the 
siRNA-mediated depletion of SRSF6 (Figure 7D), but we observed 
no such effect with depletion of SRSF1 protein, which was used as 
a control because it does not associate with the PE (Figure 7D). 
Accordingly, the impaired ability of P3-derived iPSC-Mϕ to pro-
duce TNF-α was partially rescued by the knockdown of SRSF6, 
but not SRSF1 (Figure 7E and Supplemental Figure 12). We then 
assessed the therapeutic potential of small-molecule inhibitors 
of the CDC-like kinases (CLKs) and SR protein kinases (SRPKs) 
responsible for the phosphorylation and activation of SRSFs (49). 
We used the SPREADD (splicing reporter assay for disease genes 
with dual color) splicing reporter system (50) for quantitative mon-
itoring of the inclusion of the IKBKG PE. The GFP signal indicated 
exon 4^5 splicing, whereas the red fluorescent protein (RFP) sig-
nal identified the PE inclusion product (Figure 7F). By comparing 
splice-regulating compounds with the SPREADD reporter system, 
we were able to confirm the dose-dependent suppression of the 
IKBKG PE by the CLK inhibitor TG003 (51, 52), but not by its inac-
tive analog, TG009 (51) (Figure 7, G and H, and Supplemental Fig-
ure 13). Conversely, we found that the SRPK inhibitor SRPIN340 
(53) had no effect on IKBKG PE inclusion or skipping (Figure 7G), 
indicating a dominant role for CLKs in the regulation of the IKBKG 
PE. Finally, we investigated the consequences of CLK inhibition 
in iPSC-Mϕ from P3 and showed that TG003 treatment partially 
restored NEMO expression (Figure 7I) and TNF-α production in 
response to stimulation with LPS and IFN-γ (Figure 7J). Collec-
tively, these results indicate that SRSF6-dependent ESEs facilitate 
recognition of the suboptimal PE donor created by the IVS4+866 
ed with WT mRNA levels (Figure 5C). Collectively, these findings 
indicate that the IVS4+866 C>T mutation affects NEMO protein 
levels in a cell type–specific manner, with a more pronounced 
defect in hematopoietic (leukocytes, iPSC-MLs) than nonhema-
topoietic (fibroblasts, iPSCs, iPSC-NPs) cells. These findings are 
consistent with the clinical phenotypes of the 3 boys, the affected 
mother of P1 and P2, and the documented skewing of X inactiva-
tion in the cells of this woman.
Impaired NF-κB activation in mutant fibroblasts and iPSC- 
derived macrophages. Cells from P2 and P3 had low to unde-
tectable levels of WT NEMO protein and no detectable mutant 
NEMO protein. We assessed the functional consequences of 
this profound and purely quantitative defect by analyzing NF-κB 
activation in SV40-immortalized fibroblasts from P2 upon TNF 
receptor (TNFR) and IL-1 and TLR stimulation (Figure 6A and 
Supplemental Figure 11A). We found that IκBα degradation was 
normal, despite the very low levels of IKKα/β phosphorylation in 
response to stimulation with either TNF-α or IL-1β (Figure 6A). In 
P3 iPSC-derived macrophages (iPSC-Mϕ), we observed that NF-κB 
activation upon stimulation with LPS was impaired (Figure 6B). 
The JNK and p38 MAPK pathways, which are TAK1 dependent and 
NEMO independent, were normally activated, whereas the ERK/
MAPK pathway, which is NEMO dependent, was strongly affected 
(Figure 6B). We then measured p65 translocation to the nucleus 
by analyzing immunofluorescence in both cell types. Fibroblasts 
from P2 displayed abnormally low levels of p65 nuclear translo-
cation (Figure 6C and Supplemental Figure 11B), and these levels 
were even lower in iPSC-Mϕ from P3 (Figure 6D and Supplemen-
tal Figure 11C). We then used fibroblasts from P2 and performed 
an EMSA to determine the amounts of nuclear and DNA-binding 
NF-κB dimers in response to TNF-α or IL-1β. The cells from P2 
showed abnormally low levels of DNA-binding dimers in response 
to high concentrations of either agonist (Supplemental Figure 11D). 
We then performed ELISA to measure IL-6 and IL-8 production in 
cells treated with IL-1β, TNF-α, TNF-β, IL-17, poly (I:C), and PMA 
(Figure 6E, Supplemental Figure 11E). The production of IL-6 in 
response to all these stimuli was weaker in cells from P2, and this 
decrease was most marked in response to IL-1β. The impairment 
we saw in P2’s cells was similar to that observed in X420W-hemi-
zygous cells from a patient with a severe form of EDA-ID (9). Sim-
ilarly, in P3-derived iPSC-Mϕ, we found that TLR4 stimulation 
was impaired, as demonstrated by the quantification of TNF-α 
production (Figure 6F). Complementation of iPSCs from P3 with 
WT NEMO, but not empty plasmid, followed by differentiation 
into Mϕ (Supplemental Figure 11F), fully restored NF-κB pathway 
activation in terms of the phosphorylation of ERK (p-ERK) and 
p65 (p-p65) (Figure 6B) and p65 nuclear translocation (Figure 6D, 
and Supplemental Figure 11G), while it partially restored TNF-α 
production (Figure 6F) upon LPS stimulation. The activation of 
P3-derived PBMCs by LPS confirmed the inability of leukocytes 
to produce TNF-α in response to LPS stimulation (Supplemental 
Figure 11H). Flow cytometric analysis of the leukocytes from P3 
revealed that monocytes (CD14+) responded poorly to LPS in terms 
of TNF-α production (Supplemental Figure 11I). Overall, NF-κB 
responses to various stimuli were impaired in fibroblasts from P2, 
which had 25% of the normal level of WT NEMO protein, a pheno-
type similar to that of another EDA-ID patient with expression of 
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
9jci.org
Figure 6. NEMO insufficiency impairs NF‑κB activation in patients’ fibroblasts and iPSC‑derived Mϕ. (A) Impaired NF-κB activation in response to 
TNF-α. Time course for TNF-α–stimulated SV40-immortalized fibroblasts, showing impaired IKKα/β phosphorylation (p-IKKα/β) but no impairment of 
IκBα degradation in P2 relative to the control. (B) Impaired NF-κB and ERK activation in response to LPS in P3-derived iPSC-Mϕ. Time course for LPS- 
stimulated iPSC-Mϕ, showing impaired phosphorylation of p65 and ERK1/2, but not of p38 or JNK, which are 2 proteins activated independently of NEMO. 
NF-κB and ERK activation was rescued by reexpression of WT NEMO (P3 + NEMO). (C and D) Impaired NF-κB p65 nuclear translocation (C) in P2-derived 
SV40-immortalized fibroblasts and (D) P3-derived iPSC-Mϕ. NF-κB p65 nuclear translocation was rescued by reexpression of WT NEMO (P3 + NEMO). Data 
are shown as the mean ± SD of cells from more than 4 random fields taken from 1 well per condition, and the number of cells analyzed in each condition is 
shown in parentheses. Representative results of 3 independent experiments are shown. **P < 0.001, by 1-way ANOVA followed by Turkey’s test for multi-
ple comparisons. (E) Impaired IL-6 production in response to TNF-α, TNF-β, IL-1β, poly (I:C), IL-17, and PMA in SV40-immortalized fibroblasts from P2 and 2 
reported NEMO-deficient patients (NEMOX420W/Y and NEMOΔ4–10/Y). n = 3 or 4. (F) Impaired TNF-α production in P3-derived iPSC-Mϕ. Control and P3-derived 
iPSC-Mϕ were stimulated with LPS and IFN-γ for 4 hours before TNF-α determination by ELISA. TNF-α production of P3-derived iPSC-Mϕ was restored by 
reexpression of WT NEMO. Data are shown as the mean ± SD of 3 independent clones and are representative of 2 independent experiments. *P < 0.05, by 
unpaired, 2-tailed Student’s t test.
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findings provide insight into the levels of human NEMO proteins 
required for correct canonical NF-κB activation. The most closely 
related known mutation is located in the 5′-UTR encoding exon 
1b, the expression of which is selectively impaired (transcript 1b) 
(27). Interestingly, patients with this 5′-UTR mutation develop ID 
without EDA (27, 28), as previously reported for a few other muta-
tions of the IKBKG coding sequence (12, 21–23, 60). Little is known 
about how expression of the 4 main transcripts of IKBKG generated 
by alternative splicing of the first exon is regulated (61).
The detection and validation of disease-causing mutations 
located deep within introns is challenging (43). WGS is the best 
approach for identifying such mutations, particularly given the 
size and number of introns in the human genome (62). WES is 
not a good alternative, because it is designed to capture exons and 
flanking regions and to filter out duplicated regions and tandem 
repeats (63, 64). RNA-Seq is a possible alternative but is subject 
to several limitations: (a) mutations creating a new splice site are 
typically absent from the encoded mRNAs; (b) mutant mRNAs 
can be difficult to detect because of their instability (42); and (c) 
WT mRNA levels may be only slightly lower than usual in the test-
ed cells, in which the splicing mutation may be more leaky than 
in untested cell types underlying the disease phenotype. Careful 
quantification of WT mRNA levels by RNA-Seq and RT-qPCR 
may suggest a deep regulatory mutation, provided that the most 
appropriate cell type is studied, as shown here. Overall, WGS has 
the advantage of an unbiased capture of the entire genome, pro-
vided that the region studied is analyzed thoroughly (63, 65), as 
illustrated here for IKBKG. Moreover, WGS can be used to com-
pare any candidate variant with a revised list of existing variants 
(66–68). Indeed, we used the raw WGS data from the 1kG Project 
(66) to define an initial list of rare and common variants of IKB-
KG, with estimated MAFs, population by population. This work 
provides a simple platform for estimating the potential impact 
of any variant of IKBKG. For example, we found that 3 variants 
previously reported to be disease causing (E57K, D113N, and 
Q183H) (16, 69–71) are actually present in the general population 
and are therefore unlikely to be responsible for IP or EDA-ID. Two 
of these variants have not been found in the homozygous state in 
females or in the hemizygous state in males. However, E57K is 
frequent (MAF = 1.1 × 10–3) and has been found in 67 hemizygous 
males, strongly suggesting that this variant does not cause EDA-
ID, despite having been described as hypomorphic (69, 70, 72).
This and other reports (e.g., for Usher syndrome; ref. 37) high-
light the importance of searching for deep intronic mutations by 
WGS before considering alternative genetic etiologies, particular-
ly for conditions in which most patients are found to have muta-
tions of a single gene, as is the case for IKBKG (42). AD EDA-ID 
due to IκBα GOF mutations is very rare (29, 30). The discovery of a 
novel genetic etiology may itself require searches for deep intronic 
mutations, as illustrated by XR-PDR (39, 40). This approach may 
also be of interest for other known disease-causing loci, which, 
like IKBKG, are part of a single, long duplicated region (e.g., neu-
rofibromatosis 1 [NF1] [ref. 73] and Charcot-Marie-Tooth disease 
[CMT1A] [refs. 74 and 75]). The number of variants in such dupli-
cations is typically underestimated. As much as 5.4% of the human 
genome is duplicated (≥1 kb and ≥90% identity) (75, 76 ). At least 
1 gene associated with a primary ID (NCF1, encoding P47-phox) 
C>T mutation and that the CLK inhibitor TG003 exerts its thera-
peutic effects by restoring the normal splicing of IKBKG.
Discussion
We report what to our knowledge is the first deep intronic vari-
ant of IKBKG as a genetic etiology of mild XD-IP in a mother 
and severe XR-EDA-ID in 3 boys from 2 unrelated families. IKB-
KG mutations were first reported in families with IP or EDA-
ID in 2000, but no genetic etiology has yet been identified for a 
small but significant proportion of these individuals (10%) (7, 18). 
IVS4+866 C>T is located deep enough in the intron to be missed 
by classical approaches, including WES and the Sanger sequencing 
of exons and flanking intronic regions. We believe this is the first 
disease-causing mutation of IKBKG to be identified outside the 
exons and flanking intronic regions. This mutation is also located 
outside the intronic regions covered by WES. Moreover, the new-
ly created mRNA was not detectable by Sanger sequencing of the 
cDNA obtained from patients’ fibroblasts, given the nonsense- 
mediated decay of the mutant transcripts, which were present at 
much lower levels than were WT transcripts. These findings con-
trast with those of all previous reports concerning IKBKG muta-
tions or their impact on mRNA structure based on Sanger sequenc-
ing after cDNA-PCR (8–10, 13, 19–22, 24–27, 54–59). IVS4+866 
C>T underlies a purely quantitative defect of the NEMO protein, 
given both the suboptimal nature of the new splicing donor site and 
the nonsense-mediated decay of the mutant transcripts, resulting 
in a detectable expression of the WT protein and a total absence 
of the mutant protein. We provide what we believe to be the first 
description of EDA-ID due to a purely quantitative NEMO defect 
(IP often being caused by a complete lack of NEMO protein). These 
Figure 7. The CLK inhibitor TG003 suppresses IVS4+866 C>T–induced PE 
inclusion to restore the production of a functional NEMO protein. (A) 
Genomic sequence surrounding the 44-bp PE of IKBKG. Black bars indicate 
the RNA sequences used for the pulldown assays (PE-5′ and PE-3′, WT, 
and IVS4+866 C>T). (B) Western blot of RNA-pulldown products (WT and 
IVS4+866 C>T) for U1snRNP subunits (U1-70k, U1-A, U1-C, and SmB/B′).  
(C) Western blot of RNA-pulldown products (PE-5′, PE-3′, WT, and 
IVS4+866 C>T) for phosphorylated SR proteins. (D) Western blot of 
P3-derived iPSC-Mϕ transfected with nonspecific siRNA or SRSF1-spe-
cific or SRSF6-specific siRNA. β-Actin served as the internal control. (E) 
TNF-α production by P3-derived iPSC-Mϕ transfected with nonspecific, 
SRSF1-specific, or SRSF6-specific siRNA for 72 hours was evaluated 4 
hours after stimulation with LPS and IFN-γ (n = 3). (F) Diagram of the 
SPREADD reporter for IKBKG exons 4–5 with the IVS4+866 C>T muta-
tion. The GFP signal indicates IKBKG exon 4^5 splicing, whereas the RFP 
signal indicates inclusion of the 44-nt PE. (G) The intensities of green 
and red fluorescence were quantified in HeLa cells transfected with the 
IKBKG (IVS4+866 C>T) SPREADD vector and treated with small-molecule 
compounds (TG003, TG009, and SRPIN340) or not (0.1% DMSO) for 24 
hours. Dot plots represent the GFP/RFP ratio of 6 random fields (80–100 
fluorescence-positive cells/field) from a single experiment. **P < 0.001. 
(H) Representative fluorescence micrographs of cells treated with 10 μM 
TG003 or 0.1% DMSO following transfection with the IKBKG (IVS4+866 
C>T) SPREADD vector. Nuclei were counterstained with Hoechst 33342. 
Scale bars: 200 μm. (I) Western blot of NEMO and β-actin for protein 
extracts from P3-derived or control iPSC-Mϕ. (J) TNF-α production by 
P3-derived iPSC-Mϕ stimulated with LPS and IFN-γ for 4 hours, with or 
without TG003 pretreatment. Data are presented as the mean ± SD of 3 
independent experiments using a representative clone. *P < 0.05, by 1-way 
ANOVA followed by Dunnett’s test.
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inverse correlation was found between the expression levels of 
WT IKBKG and SRSF6 in iPSCs, iPSC-Mϕ, or iPSC-NPs (data not 
shown). Instead, this observation suggests that variations in the 
expression levels and/or activity of various CLK isoforms medi-
ate the cell type–dependent pattern of IKBKG splicing. Indeed, we 
found that the levels of IKBKG transcripts generated varied con-
siderably between cell types in the healthy controls (Figure 4E, 
Figure 5C, and Supplemental Table 4). Furthermore, the aberrant 
splicing caused by IVS4+886 C>T was more common in hemato-
poietic cells, which produce smaller numbers of WT full-length 
IKBKG transcripts. This variation in IKBKG splicing highlights 
the importance of using appropriate cell types for mRNA analysis, 
whether for diagnostic purposes or for the evaluation of therapeu-
tic compounds. This observation also suggests that deep intronic 
mutations that create suboptimal splice sites probably underlie a 
considerable diversity of cellular and clinical phenotypes, includ-
ing some involving known disease-causing loci. For example, the 
IVS4+866 C>T mutation underlies a very severe ID with very mild 
developmental phenotypes, whereas other deep intronic muta-
tions in IKBKG might underlie severe developmental phenotypes 
in the absence of overt ID.
These findings led us to develop a therapeutic strategy that 
involves the use of a CLK inhibitor to overcome the PE inclusion 
caused by IVS4+886 C>T. The restoration of NEMO protein pro-
duction and function, with normal responses to LPS in patients’ 
iPSC-Mϕ, as shown by assessments of cytokine production, pro-
vided a first demonstration of proof of concept for this approach. 
In addition to the IVS4+866 C>T mutation of IKBKG, recent WGS 
studies have suggested that many disease-causing deep intronic 
mutations have gone undiscovered in WES studies (41, 42, 81, 82). 
As highlighted by the IVS4+866 C>T mutation of IKBKG, those 
PEs often result from weak or suboptimal splice sites (donor and/
or acceptor), as the sites used are not authentic or canonical splice 
sites in most cases (42). PE recognition also depends on splicing 
enhancers in cis and their corresponding trans-acting factors, such 
as SRSF6, for the IVS4+866 C>T–dependent PE. These factors 
facilitate the splicing reaction by promoting the recruitment of 
spliceosomal components. In this respect, other genetic disorders 
attributable to similar PEs would also benefit from the CLK-tar-
geting strategy described here. Indeed, we have confirmed similar 
therapeutic effects for small-molecule compounds targeting CLK 
and other factors by preventing the recognition of pathogenic PEs 
in other genetic disorders (our unpublished observations). More-
over, the target selectivity of CLK inhibitors, each of which affects 
only a subset of SR protein–dependent exons, with minimal effects 
on transcriptome profiles (ref. 83 and our unpublished observa-
tions), is also a considerable advantage over conventional spliceo-
somal inhibitors, which target constitutive splicing factors (e.g., 
spliceostatin A and E7107 for SF3B) (84–86), resulting in a general 
toxicity due to a global arrest of splicing reactions (87–89). Collec-
tively, our findings pave the way for novel treatments of PE-asso-
ciated human genetic diseases through the selective manipulation 
of splicing with rationally designed small-molecule compounds.
Methods
A complete description of the methods is provided in the Supplemen-
tal Methods.
(76) and 29 genes associated with other diseases are completely or 
partially duplicated in the human genome, resulting in a scarcity 
of reliable information concerning these loci (76). In the present 
work, we provide proof of principle that the paucity of information 
for duplicated regions can be overcome by reanalyzing NGS data, 
not only to facilitate the detection and selection of disease-caus-
ing mutations, but also to identify common and rare variants in 
specific populations. Pre-mRNAs contain 10 times as many non-
coding nucleotides, mostly in introns, than do coding nucleotides, 
but the potential impact of intronic mutations is probably underes-
timated. Damage other than interference with the splicing process 
may also occur. In this respect, one of the difficulties in the identi-
fication of deep intronic variants is the paucity of software capable 
of reliably predicting the impact of such mutations. For example, 
the IVS4+866 C>T mutation is considered benign by Mutation-
Taster (77) and has a combined annotation-dependent depletion 
(CADD) score of only 1.02, well below the mutation significance 
cutoff (MSC) of IKBKG and the CADD score of all other proven 
disease-causing IKBKG mutations (78–80). Moreover, none of the 
splicing software used to annotate the new splice site created by 
IVS4+866 C>T can be used to scan WGS data. Overall, our find-
ings argue for the development of computational and experimen-
tal approaches for the detection and validation of deep intronic 
mutations in patients with unexplained genetic disorders.
This study is also interesting in terms of the cell type–depen-
dent variability in aberrant splicing levels observed, hinting at 
potential therapeutic approaches. Indeed, residual WT IKBKG 
mRNA levels ranged from barely detectable in leukocytes, to 3% in 
iPSC-Mϕ, and up to 35% in iPSC-NPs. We found that a NEMO pro-
tein level of approximately 25% was insufficient for correct NF-κB 
activation in fibroblasts. However, the clinical consequences, in 
terms of IP and EDA, were mild. The WT NEMO levels in leuko-
cytes and iPSC-Mϕ were lower and more detrimental. This unequal 
distribution probably explains the severity of the ID in the 3 boys 
who died from infection in their first year of life. This observation 
has interesting implications in terms of human genetics. Coding 
nonsynonymous mutations or mutations that impair canonical 
splice sites are more likely to have similar consequences across cell 
types, in terms of protein levels, than mutations that create nonca-
nonical or suboptimal splice sites in the middle of introns, as shown 
in this work. Deep intronic mutations that create splice sites prob-
ably generate a considerable diversity of cellular and clinical phe-
notypes. In this case, it is possible to draw conclusions, thanks to a 
unique feature of the IVS4+866 C>T mutation, which is recurrent 
because of a hotspot, in 2 families of different ancestries (British 
and Japanese). Both the cellular and clinical phenotypes can be 
attributed, with confidence, to the mutation itself. It has a robust 
impact, as it was detected in the context of 2 different genetic back-
grounds. The rest of the patients’ genetic makeup is unlikely to be 
the main driver of this particular phenotype.
We have also determined the mechanisms underlying the 
creation of the IKBKG PE. The IVS4+866 C>T mutation creates 
a suboptimal donor site by improving base pairing to U1snRNA, 
and CLK-regulated SRSF6 provides the ESE activity required for 
PE donor recognition. However, the differences in aberrant IKB-
KG splicing between cell types (Figure 4E and Figure 5C) cannot 
be explained solely by the level of SRSF6 expression, as no clear 
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